

Cancer in Pregnancy and Lactation: The Motherisk Guide





Cancer in Pregnancy and Lactation: The Motherisk Guide

Edited by

Gideon Koren

Founder and Director, Motherisk Program and Professor of Pediatrics, Pharmacology, Pharmacy and Medical Genetics, University of Toronto, Canada.

Michael Lishner

Professor of Medicine, Sackler Faculty of Medicine, Tel Aviv University and Head of Department of Medicine A, Meir Hospital, Kfar Saba, Israel.



> CAMBRIDGE UNIVERSITY PRESS Cambridge, New York, Melbourne, Madrid, Cape Town, Singapore, São Paulo, Delhi, Tokyo, Mexico City

Cambridge University Press The Edinburgh Building, Cambridge CB2 8RU, UK

Published in the United States of America by Cambridge University Press, New York

www.cambridge.org Information on this title: www.cambridge.org/9781107006133

© Cambridge University Press 2011

This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press.

First published 2011

Printed in the United Kingdom at the University Press, Cambridge

A catalog record for this publication is available from the British Library

 $Library\ of\ Congress\ Cataloging-in-Publication\ Data$

Cancer in pregnancy and lactation : the Motherisk guide / edited by Gideon Koren, Michael Lishner.

p. ; cm. Includes bibliographical references and index. ISBN 978-1-107-00613-3 (Hardback)

Cancer in pregnancy.
 Pregnancy-Complications.
 Fetus-Effect of drugs on.
 Lactation-Effect of drugs on.
 Koren, Gideon, 1947 Lishner, M. (Michael)
 Motherisk Program.

[DNLM: 1. Pregnancy Complications, Neoplastic. 2. Fetus-drug effects. 3. Fetus-radiation effects. 4. Lactation-drug effects.
5. Lactation-radiation effects. 6. Prenatal Exposure Delayed Effects. WQ 240]

RG580.C3C354 2011 618.3'268-dc23

2011015544

ISBN 978-1-107-00613-3 Hardback

Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party internet Web sites referred to in this publication, and does not guarantee that any content on such websites is, or will remain, accurate or appropriate.

Every effort has been made in preparing this book to provide accurate and up-to-date information which is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use.



Contents

Preface vii Acknowledgement viii List of contributors ix

Section 1 — Specific tumors during pregnancy

- 1. **Bone malignancies in pregnancy**Michael Lishner and Alla Osadchy
- 2. **Breast cancer and pregnancy** 3 Liat Mlynarsky and Michael Lishner
- Cervical cancer during pregnancy 8
 Asnat Walfisch
- Hepatocellular carcinoma in pregnancy 16
 Parvaneh Yazdani-Brojeni and Michael Lishner
- 5. **Hodgkin's lymphoma in pregnancy** 18 David Pereg and Michael Lishner
- 6. Intracranial tumors in pregnancy 21
 Michael Lishner and Geert W. 't Jong
- Treatment of acute and chronic leukemia during pregnancy 24
 Tal Shapira-Rotenberg and Michael Lishner
- 8. **Lung cancer and pregnancy** 33 Hisaki Fujii and Michael Lishner
- Malignant melanoma and pregnancy 40
 Michael Lishner and Michael P. Tan
- Non-Hodgkin's lymphoma during pregnancy 49
 David Pereg and Michael Lishner

- 11. **Ovarian tumors and pregnancy** 53 Rinat Hackmon
- 12. **Thyroid cancer and pregnancy** 60 Michael P. Tan

Section 2 — Fetal effects of cancer treatments and interventions

- 13. Pregnancy and radiation 69Eyal Fenig
- 14. Chemotherapy during pregnancy 79Israel Mazin, David Pereg, and Michael Lishner
- Nonobstetrical surgical interventions during pregnancy 95Bi Lan Wo, Angela Mallozzi, and Alon Shrim

Section 3 — Management of maternal complications during treatment

- 16. Management of complications associated with cancer or antineoplastic treatment during pregnancy 117 Michael P. Tan
- 17. Management of nutritional problems in the pregnant cancer patient 128 Deborah A. Kennedy

٧



vi Contents

- 18. Pharmacological and nonpharmacological treatment of chemotherapy-induced nausea and vomiting 134 Caroline Maltepe
- Fertility considerations and methods of fertility preservation in patients undergoing treatment for cancer 143 Avi Leader

Section 4 — Long-term effects of in utero exposure on children

- 20. Long-term neurodevelopment of children exposed in utero to treatment for maternal cancer 157 Irena Nulman, Claire Tobias, BA, and Elizabeth Uleryk
- 21. Fertility of children exposed *in utero* to chemotherapy 176Tal Schechter and Ronen Loebstein

- 22. Lactation and cancer chemotherapy 179Taro Kamiya and Shinya Ito
- 23. Breast cancer and pregnancy:
 critical review of the effects of
 prior and subsequent pregnancy
 on the prognosis of young
 women with breast
 tumor 189
 Nava Siegelmann-Danieli and Ronen
 Loebstein
- 24. Effects of the placenta on metastatic breast cancer 195
 Shelly Tartakover-Matalon, Liat Drucker, and Michael Lishner

Index 206



Preface

Cancer in pregnancy, the tragic collusion of the best time in a woman's life with her worst of times, creates a serious clinical and ethical challenge. The very drugs that can eradicate rapidly growing cancer may damage the rapidly growing embryo.

Cancer is the second leading cause of death among women during their reproductive years, yet sources of concise data and guidance for the management of cancer in pregnancy are scarce. *Cancer in Pregnancy and Lactation: The Motherisk Guide* fills that resource gap as it contains updated data published over the past 5 years.

Written by a dedicated group of experts in the fields of clinical pharmacology, maternal–fetal toxicology, and hemato-oncology, this *Guide* contains the evidence-based information physicians need to address complex issues of maternal diagnosis, treatment, prognosis, and long-term impact on the unborn child.

This book is complemented by the Motherisk On-line Cancer in Pregnancy Consultative Forum. The Forum provides clinicians with ready access to expert guidance and a place to share their clinical experiences. Operational since 2000, the on-line Consultative Forum is receiving questions from individuals throughout the world. Questions and comments to the Forum are reviewed and answered by Consortium of Cancer in Pregnancy Evidence (CCoPE) members.

We invite you to visit the Forum at www.motherisk.org/cforum, review past questions and answers, and submit your own queries and comments. For as more and more clinicians engage in the informed dialog that this *Guide* and the Consultative Forum promote, their shared insights will help to generate new knowledge. We can think of no more effective way to advance the cause of science while also addressing immediate, life-threatening clinical issues.

Gideon Koren, MD Michael Lishner, MD



Acknowledgement

Supported by an unrestricted grant by Shoppers Drug Mart, Canada

viii



Contributors

Liat Drucker, MD

Oncogenetic Laboratory, Meir Medical Center, Kfar Saba, Israel

Eyal Fenig, MD

Professor of Oncology, Head of Radiotherapy, Davidoff Center, Rabbin Medical Center, Petha Tikva, Israel

Hisaki Fujii, MD, PhD

Clinical Fellow, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Rinat Hackmon, MD

High Pregnancy Risk Fellow, University of Toronto, Saint Michael's Hospital, Toronto, Ontario, Canada

Shinya Ito, MD, FRCPC

Professor and Division Head, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Geert W. 't Jong, MD, PhD

Fellow in Clinical Pharmacology, Division of Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Taro Kamiya, MD

Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Deborah A. Kennedy, MBA, ND

Graduate Student, Leslie Dan Faculty of Pharmacology, University of Toronto, The Hospital for Sick Children, Toronto, Ontario, Canada

Avi Leader, MD

Resident, Department of Medicine A, Meir Medical Center, Kfar Saba, Israel

Michael Lishner, MD

Professor of Medicine, Sackler Faculty of Medicine, Tel Aviv University and Head of Department of Medicine A, Meir Hospital, Kfar Saba, Israel

Ronen Loebstein, MD

Director, Institute of Clinical Pharmacology and Toxicology, Sheba Medical Center, Tel Hashomer, Israel

Angela Mallozzi, MD

Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Royal Victoria Hospital, Montreal, Quebec, Canada

Caroline Maltepe, BA

Coordinator, Motherisk NVP Helpline, The Motherisk Program, The Hospital for Sick Children, Toronto, Ontario, Canada

Israel Mazin, MD

Department of Medicine, Meir Medical Center, Kfar Saba, Israel

Liat Mlynarsky, MD

Meir Medical Center, Kfar Saba, Israel

Irena Nulman, MD, FRCPC Neurology, PhD

Associate Director, Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto; Associate Professor of Pediatrics, and Program Director, Fellowship Training Program in Clinical Pharmacology, University of Toronto, Ontario, Canada

İΧ



List of contributors

Alla Osadchy, MD

Clinical Fellow, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

David Pereg, MD

Doctor of Internal Medicine and Cardiology, Meir Medical Center, Kfar Saba, Israel

Tal Schechter, MD

Assistant Professor of Pediatrics, Staff Physician, Division of Hematology-Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada

Tal Shapira-Rotenberg, MD

Department of Internal Medicine A, Meir Medical Center, Kfar Saba, Israel

Alon Shrim, MD

The Motherisk Program, Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Nava Siegelmann-Danieli, MD

Maccabi Health Services, Tel-Aviv, Israel

Michael P. Tan, MD, MSc

Motherisk Counselor, Division of Pharmacology and Toxicology, The Hospital for Sick Children, Toronto, Ontario, Canada

Shelly Tartakover-Matalon, PhD

Researcher, Meir Medical Center, Kfar-Saba and Tel-Aviv University, Tel-Aviv, Israel

Claire Tobias, BA

Fetal Alcohol Syndrome Clinic Coordinator, The Hospital for Sick Children, Toronto, Ontario, Canada

Elizabeth Uleryk

Library Director, The Hospital for Sick Children, Toronto, Ontario, Canada

Asnat Walfisch, MD

High Risk Pregnancy, Department of Obstetrics and Gynecology, Hilil-Yafe Medical Center, Hadera, Israel

Bi Lan Wo, MD

Fellow in Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada

Parvaneh Yazdani-Brojeni, MD

Clinical Pharmacologist, Research Fellow, The Hospital for Sick Children, Toronto, Ontario, Canada